Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vynfinit progress sees near doubling of Endocyte value

This article was originally published in Scrip

Executive Summary

Investors responded enthusiastically to two positive pieces of news from Endocyte on Friday 21 March. First, experts on the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM) recommended granting conditional marketing authorisation for Vynfinit (vintafolide) to treat women with a sub-type of platinum-resistant ovarian cancer for which there are limited approved treatment options. Second, the company reported that in the Phase IIb TARGET trial, Vynfinit plus docetaxel, as a potential second-line treatment of non-small cell lung cancer (NSCLC), met the primary endpoint of improving progression free survival versus docetaxel alone.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts